FDA Grants First US Approval for Hepatitis Delta Treatment as Gilead's Hepcludex Ends Decades Without an Option
The FDA granted accelerated approval to Hepcludex (bulevirtide-gmod) on May 22, 2026, making it the first treatment cleared for chronic hepatitis delta virus infection in the United States.
4 min read3 sources